This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paratek Pharmaceuticals Stock (NASDAQ:PRTK) 30 days 90 days 365 days Advanced Chart Get PRTK alerts:Sign Up Key Stats Today's Range$2.23▼$2.2350-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65VolumeN/AAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewParatek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.Read More… Paratek Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScorePRTK MarketRank™: Paratek Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat, and ranked 932nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Paratek Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRTK. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG1.3 / 5Environmental Score-2.98 Short InterestThere is no current short interest data available for PRTK. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Paratek Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Paratek Pharmaceuticals' insider trading history. Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTK Stock News HeadlinesOptinose CEO and other top executives exit after company's acquisition by ParatekMay 23, 2025 | bizjournals.comParatek expands commercial portfolio with OptinoseMay 22, 2025 | msn.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 28, 2025 | Augusta Precious Metals (Ad)OptiNose Shareholders Approve Merger with ParatekMay 18, 2025 | investing.comParatek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International ConferenceMay 16, 2025 | globenewswire.comHow a Bucks County firm's multiyear pursuit of a partner led to a potential $330M dealApril 11, 2025 | bizjournals.comParatek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025April 10, 2025 | globenewswire.comParatek Pharmaceuticals to acquire Optinose in $330M transactionMarch 21, 2025 | markets.businessinsider.comSee More Headlines PRTK Stock Analysis - Frequently Asked Questions How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) released its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analysts' expectations of $22.98 million. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH). Company Calendar Last Earnings11/08/2021Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.57 million Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:PRTK) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Paratek Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.